Tango Therapeutics, Inc. (TNGX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Tango Therapeutics, Inc. (TNGX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 48/100 — a percentile rank of Tango Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $4.1B |
| P / S | 76.6× |
| EV / EBITDA | -28.1× |
| Gross margin | 100.0% |
| Operating margin | -253.4% |
| Net margin | -229.9% |
| Return on equity | -12.1% |
| ROIC | -20.1% |
| Revenue growth | 121.5% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Tango Therapeutics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from Tango Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact